日本陸水学会第54回大会シンポジウム記録

The 13th Annual Conference of the United Kingdom Evaluation Society (UKES), ‘Great Expectations? Meeting the Changing Needs of Stakeholders in Evaluation’, was held in Leeds, England on 22-23 November 2007. This article is a brief report on the conference.

Presents information on ITS society conferences and meetings.

The 22nd Power and Energy Society Annual Conference was held on August 30 - September 1, 2011 at University of Fukui. The total number of technical papers was 346, and technical sessions were 43 (42 oral sessions and 1 poster session). An invited lecture, a panel discussion, technical exhibitions and two technical tours were organized. All events were very well attended and the final enrollment attained to 888 registrations. The conference was successfully closed by the great contribution of all participants. The outline of the conference is reported in this article.

Conference Report : The 39th Annual Conference of the IEEE Industrial Electronics Society (IECON 2013) November 10-13, 2013, Austria Center, Vienna, Austria

Conference Report: The 46th Annual Conference of the IEEE Industrial Electronics Society (IECON 2020) October 18-21, 2020, Virtual

A report of the 29th Conference of Japanese Society of Health Education and Promotion

IOS-01 Application Oriented Principles of Machine Learning and Data Mining(Organized Sessions in the 26th Annual Conference of the Japanese Society for Artificial Intelligence,<Special Issue>The 26th Annual Conference of the Japanese Society for Artificial Intelligence)

The 18th World Congress of Basic and Clinical Pharmacology (WCP2018), coordinated by IUPHAR and hosted by the Japanese Pharmacological Society and the Japanese Society of Clinical Pharmacology and Therapeutics, was held in July 2018 at the Kyoto International Conference Center, in Kyoto, Japan. Having as its main theme 'Pharmacology for the Future: Science, Drug Development and Therapeutics', WCP2018 was attended by over 4500 delegates, representing 78 countries. The present report is an overview of a symposium at WCP2018, entitled Pharmacogenomics in Special Populations, organized by IUPHAR´s Pharmacogenetics/Genomics (PGx) section. The PGx section congregates distinguished scientists from different continents, covering expertise from basic research, to clinical implementation and ethical aspects of PGx, and one of its major activities is the coordination of symposia and workshops to foster exchange of PGx knowledge (https://iuphar.org/sections-subcoms/pharmacogenetics-genomics/). The symposium attracted a large audience to listen to presentations covering various areas of research and clinical adoption of PGx in Oceania, Africa, Latin America and Asia.

This review summarizes the presentations of the night session symposium at the 91st Conference of the Japanese Prosthodontic Society, Niigata, in June, 1994. The symposium focused on the role of occlusion for the etiology in temporomandibular disorders (TMD) which has been controversial because of the lack of scientific evidence for causal relationship. To improve the understanding of TMD, the previously reported findings of the etiology, examination methods, diagnostic classification and effectiveness of treatment for TMD were reviewed. In conclusion, morphological and mechanical factors of occlusion, such as the amount of overbite and overjet, anterior open bite, crossbite, Angle malocclusions, the amount of RCP-ICP slides, and unilateral RCP contacts, which the recent reviews handled, were not sufficient to understand the association between the occlusion and TMD. It was proposed that assessment of occlusion in TMD should be based upon more physiological and biomechanical points of view in the masticatory system.

BackgroundThe development of novel antitumor agents and accompanying biomarkers has improved survival across several tumor types. Previously, we published provisional clinical opinion for the diagnosis and use of immunotherapy in patients with deficient DNA mismatch repair tumors. Recently, efficacy of tropomyosin receptor kinase inhibitors against neurotrophic receptor tyrosine kinase (NTRK) fusion gene-positive advanced solid tumors have been established as the second tumor-agnostic treatment, making it necessary to develop the guideline prioritized for these patients.MethodsClinical questions regarding medical care were formulated for patients with NTRK-positive advanced solid tumors. Relevant publications were searched by PubMed and Cochrane Database. Critical publications and conference reports were added manually. Systematic reviews were performed for each clinical question for the purpose of developing clinical recommendations. The committee members identified by Japan Society of Clinical Oncology (JSCO) and Japanese Society of Medical Oncology (JSMO) voted to determine the level of each recommendation considering the strength of evidence, expected risks and benefits to patients, and other related factors. Thereafter, a peer review by experts nominated from JSCO, JSMO, and Japanese Society of Pediatric Hematology/Oncology, and the public comments among all Societies’ members was done.ResultsThe current guideline describes 3 clinical questions and 15 recommendations for whom, when, and how NTRK fusion should be tested, and what is recommended for patients with NTRK fusion-positive advanced solid tumors.ConclusionIn the NTRK guideline, the committee proposed 15 recommendations for performing NTRK testing properly to select patients who are likely to benefit from tropomyosin receptor kinase inhibitors.

Report on the 2018 annual conference of the Japanese Society of Physical Hydrology

Report on the 70th Annual Conference of the Japanese Society for Dance Research

Report by General Chair(<Special Issue>The 27th Annual Conference of the Japanese Society for Artificial Intelligence)

Challenging the gap between evidence and practice: Message for the 31st Annual Conference of the Japanese Society of Health Education and Promotion in Tokyo

陸水物理研究会2015年大会の報告